Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-IGFBP2 plasmid DNA vaccine AST-201

A polyepitope plasmid DNA therapeutic cancer vaccine containing the mammalian expression vector pUMVC3 encoding multiple epitopes derived from tumor-associated antigens (TAAs): human insulin-like growth factor-binding protein 2 (IGFBP2), with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination, anti-IGFBP2 plasmid DNA vaccine AST-201 enters cells which process the plasmid, and express the epitopes and present them to antigen-presenting cells (APCs). This activates the immune system to mount a combined response from specific T-helper type 1 (Th1) cells, memory T-cells and cytotoxic T lymphocytes (CTL) against IGFBP2-expressing tumor cells. IGFBP2, overexpressed in certain tumor cell types, plays a key role in cellular proliferation and survival.
Synonym:IGFBP2 vaccine AST201
pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine AST201
pUMVC3-hIGFBP-2-based vaccine AST201
therapeutic cancer vaccine AST-201
Code name:AST 201
AST-201
AST201
Search NCI's Drug Dictionary